Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report), Merit Medical Systems (MMSI – Research Report) and Masimo (MASI – Research Report).
Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $500.00. The company’s shares closed last Monday at $404.65, close to its 52-week high of $413.00.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $405.90, a -1.4% downside from current levels. In a report issued on December 5, Cantor Fitzgerald also maintained a Buy rating on the stock with a $380.00 price target.
See today’s best-performing stocks on TipRanks >>
Merit Medical Systems (MMSI)
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Merit Medical Systems yesterday and set a price target of $81.00. The company’s shares closed last Monday at $71.25.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merit Medical Systems with a $84.00 average price target.
Masimo (MASI)
In a report released yesterday, Vik Chopra from Wells Fargo maintained a Hold rating on Masimo, with a price target of $81.00. The company’s shares closed last Monday at $115.22.
According to TipRanks.com, Chopra is a 2-star analyst with an average return of
Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $89.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRTX:
- Biotech Alert: Searches spiking for these stocks today
- Crispr Therapeutics positioned for European approval, says Piper Sandler
- Vertex Pharmaceuticals reports CHMP opinion for conditional approval of Casdevy
- Vertex Pharmaceuticals price target raised by $31 at Barclays, here’s why
- Vertex Pharmaceuticals price target raised to $446 from $415 at Barclays
